Geneva Capital Management LLC Sells 4,598 Shares of Vericel Co. (NASDAQ:VCEL)

Geneva Capital Management LLC cut its stake in shares of Vericel Co. (NASDAQ:VCEL) by 0.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,099,788 shares of the biotechnology company’s stock after selling 4,598 shares during the quarter. Geneva Capital Management LLC owned approximately 2.23% of Vericel worth $60,389,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Creative Planning bought a new position in shares of Vericel in the third quarter valued at $230,000. International Assets Investment Management LLC lifted its stake in shares of Vericel by 4,126.7% in the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 619 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 405 shares in the last quarter. Summit Global Investments lifted its stake in shares of Vericel by 105.4% in the third quarter. Summit Global Investments now owns 20,831 shares of the biotechnology company’s stock valued at $880,000 after buying an additional 10,691 shares in the last quarter. Finally, Atria Investments Inc lifted its stake in shares of Vericel by 21.6% in the third quarter. Atria Investments Inc now owns 7,768 shares of the biotechnology company’s stock valued at $328,000 after buying an additional 1,378 shares in the last quarter.

Insider Buying and Selling

In other news, insider Jonathan Siegal sold 3,908 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total transaction of $242,256.92. Following the sale, the insider now owns 1,206 shares in the company, valued at approximately $74,759.94. The trade was a 76.42 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Robert L. Md Zerbe sold 2,500 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the sale, the director now directly owns 26,595 shares in the company, valued at $1,662,187.50. This trade represents a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 7,500 shares of company stock valued at $466,200 over the last three months. 5.20% of the stock is owned by company insiders.

Vericel Stock Performance

Shares of VCEL opened at $51.53 on Thursday. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of 858.98 and a beta of 1.72. Vericel Co. has a fifty-two week low of $39.12 and a fifty-two week high of $63.00. The firm has a 50 day moving average price of $56.81 and a 200-day moving average price of $51.93.

Analysts Set New Price Targets

A number of research analysts have weighed in on VCEL shares. BTIG Research raised their price objective on shares of Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Vericel in a report on Friday, February 28th. Truist Financial reiterated a “buy” rating and issued a $61.00 target price (down previously from $67.00) on shares of Vericel in a report on Monday. StockNews.com downgraded shares of Vericel from a “hold” rating to a “sell” rating in a report on Friday, February 28th. Finally, Stephens reiterated an “overweight” rating and issued a $65.00 target price on shares of Vericel in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.29.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.